Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain

Human papillomavirus (HPV) is one of the main causes of infection-related cancer. The bivalent vaccine (2vHPV) (16/18) and quadrivalent (6/11/16/18) HPV vaccine (4vHPV) have been included in the Spanish vaccination calendar since 2007. The new nonavalent HPV vaccine (9vHPV), approved in Europe in 20...

Descripción completa

Detalles Bibliográficos
Autores principales: De La Fuente, Jesús, Hernandez Aguado, Juan José, San Martín, María, Ramirez Boix, Paula, Cedillo Gómez, Sergio, López, Noelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746536/
https://www.ncbi.nlm.nih.gov/pubmed/30698488
http://dx.doi.org/10.1080/21645515.2018.1560770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746536/
https://www.ncbi.nlm.nih.gov/pubmed/30698488
http://dx.doi.org/10.1080/21645515.2018.1560770

Ejemplares similares